Simplex Trading
GALT icon

Simplex Trading’s Galectin Therapeutics GALT Stock Holding History

Simplex Trading’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
62,200
-52,200
-46% -$159K ﹤0.01% 4464
2025
Q4 		$476K Buy
114,400
+96,400
+536% +$508K ﹤0.01% 3356
2025
Q3 		$76K Buy
18,000
+2,800
+18% +$10.5K ﹤0.01% 6041
2025
Q2 		$32K Sell
15,200
-6,300
-29% -$9.43K ﹤0.01% 6338
2025
Q1 		$26K Sell
21,500
-64,900
-75% -$91K ﹤0.01% 6360
2024
Q4 		$111K Sell
86,400
-7,300
-8% -$17.5K ﹤0.01% 5077
2024
Q3 		$257K Buy
93,700
+88,400
+1,668% +$217K ﹤0.01% 4280
2024
Q2 		$11K Buy
5,300
+2,300
+77% +$6.99K ﹤0.01% 7353
2024
Q1 		$7K Buy
3,000
+1,300
+76% +$2.46K ﹤0.01% 7823
2023
Q4 		$2K Sell
1,700
-6,700
-80% -$13K ﹤0.01% 8262
2023
Q3 		$16K Sell
8,400
-400
-5% -$658 ﹤0.01% 6811
2023
Q2 		$12K Sell
8,800
-2,100
-19% -$3.56K ﹤0.01% 7232
2023
Q1 		$22K Buy
10,900
+6,300
+137% +$10.2K ﹤0.01% 6813
2022
Q4 		$5K Sell
4,600
-11,400
-71% -$15.2K ﹤0.01% 8050
2022
Q3 		$26K Buy
16,000
+6,100
+62% +$11.4K ﹤0.01% 7231
2022
Q2 		$12K Sell
9,900
-10,800
-52% -$15.5K ﹤0.01% 8120
2022
Q1 		$33K Sell
20,700
-8,300
-29% -$16.1K ﹤0.01% 7658
2021
Q4 		$60K Sell
29,000
-14,700
-34% -$42K ﹤0.01% 7003
2021
Q3 		$142K Hold
43,700
– – ﹤0.01% 6117
2021
Q2 		$139K Buy
43,700
+43,417
+15,342% +$155K ﹤0.01% 6246
2021
Q1 		$61K Sell
283
-279
-50% -$625 ﹤0.01% 6365
2020
Q4 		$125K Buy
562
+65
+13% +$171 ﹤0.01% 5204
2020
Q3 		$132K Buy
497
+280
+129% +$784 ﹤0.01% 4594
2020
Q2 		$66K Sell
217
-80
-27% -$201 ﹤0.01% 5227
2020
Q1 		$58K Sell
297
-14
-5% -$34 ﹤0.01% 4975
2019
Q4 		$88K Sell
311
-16
-5% -$56 ﹤0.01% 4644
2019
Q3 		$120K Sell
327
-2
-0.6% -$7 ﹤0.01% 4120
2019
Q2 		$136K Sell
329
-34
-9% -$147 ﹤0.01% 3875
2019
Q1 		$185K Buy
363
+322
+785% +$1.55K ﹤0.01% 3705
2018
Q4 		$14K Sell
41
-891
-96% -$4.26K ﹤0.01% 5613
2018
Q3 		$560K Buy
932
+583
+167% +$3.21K ﹤0.01% 2510
2018
Q2 		$221K Sell
349
-4
-1% -$19 ﹤0.01% 3363
2018
Q1 		$61K Buy
353
+187
+113% +$871 ﹤0.01% 2236
2017
Q4 		$16K Buy
166
+101
+155% +$255 ﹤0.01% 3500
2017
Q3 		$3K Buy
65
+8
+14% +$16 ﹤0.01% 4778
2017
Q2 		$2K Buy
+57
New +$152 ﹤0.01% 5237
2017
Q1 		– Sell
-233
Closed -$4K – 6347
2016
Q4 		$4K Sell
233
-137
-37% -$122 ﹤0.01% 4520
2016
Q3 		$4K Buy
370
+302
+444% +$537 ﹤0.01% 4444
2016
Q2 		$1K Buy
+68
New +$100 ﹤0.01% 5284

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Simplex Trading's GALT Position: Q1 2026 in Review

Simplex Trading increased its Galectin Therapeutics (GALT) stake by 1,406% in Q1 2026, buying an estimated $239K and bringing the position to 84,000 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

Simplex Trading first reported a position in GALT in Q4 2014 and has held it in 33 quarters since. The position peaked at $285K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Simplex Trading held 84,000 shares of Galectin Therapeutics worth $234K as of Q1 2026.
  • Simplex Trading bought 78,421 Galectin Therapeutics shares in Q1 2026, an estimated $239K.
  • Galectin Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4115 holding.
  • Simplex Trading first reported a position in Galectin Therapeutics in Q4 2014 and has held it in 33 quarters since.
  • Simplex Trading's Galectin Therapeutics position peaked at $285K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.